Living Legends in Psychopharmacology 2026, Translating Neuroscience, Precision Medicine, and AI into Breakthrough Treatment for Complex Psychiatric Disorders

Living Legends in Psychopharmacology 2026, Translating Neuroscience, Precision Medicine, and AI into Breakthrough Treatment for Complex Psychiatric Disorders is organized by University of Miami Miller School of Medicine Division of Continuing Medical Education and will be held from Apr 17 - 18, 2026 at The Sunny Miami Sunny Isles Beach, Curio Collection by Hilton, Sunny Isles Beach, Florida, United States of America.

Description:
Join world-renowned leaders in the field for a transformative two-day conference at the leading edge of psychiatric innovation. Living Legends in Psychopharmacology 2026 brings together pioneering minds to explore the frontiers of neuroscience, precision medicine, and AI – translating cutting-edge discoveries into real-world strategies for even the most complex, treatment-resistant cases.

Designed to be both visionary and clinically grounded, this immersive experience offers deep dives into Personalized Psychiatry, including pharmacogenomics, blood level monitoring, and pharmacokinetic tailoring to optimize medication sequencing and dosing. Attendees will explore next-generation treatments such as ketamine, ECT, TMS, and psychedelic-assisted therapies, as well as multimodal augmentation strategies for refractory mood and psychotic disorders.

Foundational sessions in Neurobiology will examine core systems of neurotransmission, receptor dynamics, gene-environment interplay, and epigenetic regulation – providing a scientific framework for truly individualized care. Targeted modules on Schizophrenia, Bipolar Disorder, and Mood Disorders will focus on early intervention, treatment resistance, and emerging pharmacologic innovations.

Additional sessions will cover the latest in Anxiety and PTSD, including critical discussions on benzodiazepine stewardship and promising novel agents. A dedicated focus on Special Populations – spanning women’s mental health, pediatric and geriatric psychiatry, and autism spectrum disorders – ensures a breadth of relevance across the clinical landscape. Attendees will also deepen their understanding of Sleep and Substance Use Disorders, exploring neurobiological mechanisms and evolving therapeutic approaches.

Furthermore, a timely and thought-provoking session on the Ethical Use of AI in Psychiatry will address data privacy, algorithmic bias, and how artificial intelligence can support – rather than supplant – the essential human connection at the heart of psychiatric care.

Anchored in real-world case discussions, interactive panels, and unparalleled access to field-defining experts, this course equips clinicians with the insights, tools, and science to meet the demands of 21st-century psychiatry – where complexity is the norm, and precision is the goal.

Objectives:
Course Highlights:

• Legendary, field-defining faculty
• Current and emerging evidence-based treatments
• Innovations in the management of schizophrenia and bipolar disorder
• Advances in the treatment of bipolar depression and treatment-resistant depression
• Psychedelic-assisted therapy and ketamine: indications, mechanisms, and integration
• Next-generation neuromodulation: TMS, ECT, and beyond
• Psychopharmacologic strategies for anxiety syndromes, autism spectrum disorders, and sleep disturbances
• Comprehensive updates in PTSD treatment
• The evolving interface of psychiatry with neurology and primary care medicine
• Pharmacologic approaches to alcohol and substance use disorders
• Psychopharmacologic care across the reproductive lifespan in women’s mental health
• Age-sensitive psychopharmacology for children, adolescents, and older adults 
• The ethical and clinical implications of Artificial Intelligence in psychiatry

Course Objectives:
Upon completion of this course, participants will be able to:

• Appy principles of personalized psychiatry—including pharmacogenomic testing, blood level monitoring, and drug-drug interaction analysis—to optimize psychotropic medication regimens in treatment-resistant patients.
• Evaluate and implement evidence-based use of cutting-edge therapies such as ketamine, ECT, TMS, and psychedelic-assisted treatments in the management of mood and psychotic disorders.
• Integrate current neurobiological insights—including neurotransmitter systems, receptor signaling, and gene-environment interactions—into the diagnosis and treatment planning of complex psychiatric
• conditions.
• Differentiate treatment strategies for schizophrenia and bipolar disorder, including approaches for prodromal states, first-episode psychosis, and long-term management of chronic or refractory illness.
• Select and sequence appropriate pharmacologic and somatic treatments for major depressive disorder based on pathophysiologic mechanisms such as inflammation, neuroplasticity, and stress response systems.
• Formulate individualized treatment plans for anxiety disorders and PTSD, incorporating both traditional pharmacotherapy and emerging modalities like ketamine and psychedelic-assisted psychotherapy.
• Design safe and effective psychopharmacologic treatment strategies for women across the reproductive lifespan, with consideration for hormonal fluctuations, pregnancy, and postpartum care.
• Interpret and apply recent findings in pediatric, adolescent, and geriatric psychiatry to inform age-appropriate diagnosis, medication selection, and monitoring strategies.
• Assess and treat autism spectrum disorders using advanced pharmacologic approaches grounded in the latest research on neurodevelopment and neurobiology.
• Diagnose and manage sleep disorders and substance use disorders with a focus on neurobiological mechanisms, risk mitigation, and integrated pharmacologic and behavioral treatments.
• Translate emerging clinical research into practical decision-making tools for the treatment of complex psychiatric cases, including those involving multimorbidity and polypharmacy.
• Demonstrate enhanced clinical communication and therapeutic alliance skills that support adherence, safety, and patient-centered care in psychopharmacologic practice.
• Analyze the ethical implications of integrating artificial intelligence in psychiatric care, focusing on data privacy, algorithmic biases, and the preservation of the therapeutic alliance, while identifying strategies to
• ensure that AI tools enhance, rather than replace, patient-centered care.